Literature DB >> 7801220

The vascular endothelium as a regulator of the ocular circulation: a new concept in ophthalmology?

I O Haefliger1, P Meyer, J Flammer, T F Lüscher.   

Abstract

The endothelium influences local vascular tone by releasing endothelium-derived relaxing factors such as nitric oxide, prostacyclin and a putative hyperpolarizing factor. In isolated ophthalmic arteries and the perfused eye, all endothelial factors importantly contribute to vascular regulation. In larger ophthalmic vessels, this is due to their effects on vascular smooth muscle cells; in smaller vessels, pericytes can be influenced as well. Contracting factors formed include peptide endothelin-1 and cyclooxygenase products, such as thromboxane A2 and prostaglandin H2. In the peripheral circulation endothelial dysfunction occurs under pathological conditions, both in conduit arteries and the microcirculation. An imbalance of endothelium-derived relaxing and contracting factors could be important for the development of vascular ophthalmic complications like hypertension, diabetes, arteriolosclerosis and retinal ischemia. Endothelial dysfunction may also contribute to vasospastic events in retinal migraine and some forms of low tension glaucoma associated with Raynaud phenomenon and migraine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7801220     DOI: 10.1016/0039-6257(94)90157-0

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  47 in total

1.  Coagulation pathways and diabetic retinopathy: abnormal modulation in a selected group of insulin dependent diabetic patients.

Authors:  C Giusti; R Schiaffini; C Brufani; A Pantaleo; E M Vingolo; P Gargiulo
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

Review 2.  Celecoxib, rofecoxib, and acute temporary visual impairment.

Authors:  David Morris Coulter; David Walter John Clark; Ruth Lesley Savage
Journal:  BMJ       Date:  2003-11-22

Review 3.  [Characteristic features of optic nerve ganglion cells and approaches for neuroprotection. From intracellular to capillary processes and therapeutic considerations].

Authors:  R H W Funk; K-G Schmidt
Journal:  Ophthalmologe       Date:  2004-11       Impact factor: 1.059

4.  Inverse correlation between endothelin-1-induced peripheral microvascular vasoconstriction and blood pressure in glaucoma patients.

Authors:  A Gass; J Flammer; L Linder; S C Romerio; P Gasser; W E Haefeli
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-10       Impact factor: 3.117

5.  Effect of oxygen on relaxation of retinal pericytes by sodium nitroprusside.

Authors:  I O Haefliger; Q Chen; D R Anderson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-06       Impact factor: 3.117

Review 6.  Ocular adverse effects associated with systemic medications : recognition and management.

Authors:  Ricardo M Santaella; Frederick W Fraunfelder
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Cyclic GMP, sodium nitroprusside and sodium azide reduce aqueous humour formation in the isolated arterially perfused pig eye.

Authors:  Mohammad Shahidullah; Maurice Yap; Chi-Ho To
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

8.  The role of lipid dysregulation and vascular risk factors in glaucomatous retrobulbar circulation.

Authors:  Monika Modrzejewska; Wilhelm Grzesiak; Daniel Zaborski; Anna Modrzejewska
Journal:  Bosn J Basic Med Sci       Date:  2015-03-15       Impact factor: 3.363

Review 9.  Use of isolated ocular arteries in vitro to define the pathology of vascular changes in glaucoma.

Authors:  C H Buckley; P W Hadoke; C J O'Brien
Journal:  Br J Ophthalmol       Date:  1997-07       Impact factor: 4.638

10.  Longitudinal alterations in the dynamic autoregulation of optic nerve head blood flow revealed in experimental glaucoma.

Authors:  Lin Wang; Grant Cull; Claude F Burgoyne; Simon Thompson; Brad Fortune
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-08       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.